Glass House Brands (GLAS) Amortization of Deferred Charges (2020 - 2026)
Glass House Brands' (GLAS) quarterly Amortization of Deferred Charges came in at $275000.0 in Q1 2026, down 34.21% year-on-year from $418000.0 in Q1 2025, and down 58.46% on a QoQ basis from $662000.0 in Q4 2025.
Glass House Brands (GLAS) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Glass House Brands (GLAS) has 7 years of Amortization of Deferred Charges data on file, last reported at $275000.0 in Q1 2026.
- On a quarterly basis, Amortization of Deferred Charges fell 34.21% year-over-year to $275000.0 in Q1 2026; TTM through Mar 2026 was $1.6 million, a 37.59% decrease from a year earlier, with the FY2025 full-year figure at $1.8 million, down 31.33% from the prior year.
- Amortization of Deferred Charges for Q1 2026 stood at $275000.0, down from $662000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for GLAS reached as high as $1.6 million in Q4 2023 and fell as low as -$82114.0 in Q2 2022.
- Historically, Amortization of Deferred Charges has averaged $440196.3 across 5 years, with a median of $345898.0 in 2023.
- On a YoY basis, Amortization of Deferred Charges climbed as much as 36731.74% in 2022 and fell as far as 56923.61% in 2022.
- Year by year, Amortization of Deferred Charges stood at $24746.0 in 2022, then surged by 6208.28% to $1.6 million in 2023, then decreased by 13.07% to $1.4 million in 2024, then sank by 51.22% to $662000.0 in 2025, then tumbled by 58.46% to $275000.0 in 2026.
- Per Business Quant data, the three most recent Amortization of Deferred Charges figures were $275000.0 in Q1 2026, $662000.0 in Q4 2025, and $250000.0 in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Glass House Brands | 873.84 Mn | 845.91 Mn | 10.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 275,000.00 |
| Mar 31, 2026 | 275,000.00 |
| Dec 31, 2025 | 662,000.00 |
| Dec 31, 2025 | 662,000.00 |
| Sep 30, 2025 | 250,000.00 |
| Sep 30, 2025 | 250,000.00 |
| Jun 30, 2025 | 430,000.00 |
| Jun 30, 2025 | 430,000.00 |
| Mar 31, 2025 | 418,000.00 |
| Mar 31, 2025 | 418,000.00 |
| Dec 31, 2024 | 1.36 Mn |
| Dec 31, 2024 | 1.36 Mn |
| Sep 30, 2024 | 414,000.00 |
| Sep 30, 2024 | 414,000.00 |
| Jun 30, 2024 | 402,000.00 |
| Jun 30, 2024 | 402,000.00 |
| Mar 31, 2024 | 390,000.00 |
| Mar 31, 2024 | 390,000.00 |
| Dec 31, 2023 | 1.56 Mn |
| Dec 31, 2023 | 1.56 Mn |